Cargando…

Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry

BACKGROUND: Noonan syndrome (NS) is a genetic disorder characterized by phenotypic features, including facial dysmorphology, cardiovascular anomalies, and short stature. Growth hormone (GH) has been approved by the United States Food and Drug Administration for short stature in children with NS. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Peter A, Ross, Judith, Germak, John A, Gut, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477766/ https://www.ncbi.nlm.nih.gov/pubmed/22682146 http://dx.doi.org/10.1186/1687-9856-2012-15

Ejemplares similares

Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program
por: Biller, Beverly M. K., et al.
Publicado: (2021)

The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)
por: Höybye, Charlotte, et al.
Publicado: (2013)

Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program(®)
por: Lee, Peter A, et al.
Publicado: (2011)

Noonan syndrome and Turner syndrome patients respond similarly to 4 years’ growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program
por: Lee, Peter A., et al.
Publicado: (2015)

Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program
por: Ross, Judith L, et al.
Publicado: (2015)

Developments in administration of growth hormone treatment: focus on Norditropin(®) Flexpro(®)
por: Yuen, Kevin CJ, et al.
Publicado: (2011)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021)

Factors Influencing the One- and Two-Year Growth Response in Children Treated with Growth Hormone: Analysis from an Observational Study
por: Ross, Judith, et al.
Publicado: (2010)

Genotypic Findings in Noonan and Non-Noonan RASopathies and Patient Eligibility for Growth Hormone Treatment
por: Carcavilla, Atilano, et al.
Publicado: (2023)

User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study
por: Tauber, Maithé, et al.
Publicado: (2013)

Growth hormone therapy in patients with Noonan syndrome
por: Seo, Go Hun, et al.
Publicado: (2018)

User assessment of Norditropin NordiFlex®, a new prefilled growth hormone pen: a Phase IV multicenter prospective study [Corrigendum]
Publicado: (2013)

Tegumentary manifestations of Noonan and Noonan-related syndromes
por: Quaio, Caio Robledo D'Angioli Costa, et al.
Publicado: (2013)

Effectiveness of growth hormone therapy in children with Noonan syndrome
por: Seok, Eun mi, et al.
Publicado: (2020)

Growth Hormone Deficiency in a Child with Neurofibromatosis-Noonan Syndrome
por: Vurallı, Doğuş, et al.
Publicado: (2016)

Growth, Endocrine Features, and Growth Hormone Treatment in Noonan Syndrome
por: Dahlgren, Jovanna, et al.
Publicado: (2022)

Three years of growth hormone therapy in children born small for gestational age: results from the ANSWER Program
por: Rapaport, Robert, et al.
Publicado: (2018)

Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program
por: Miller, Bradley S., et al.
Publicado: (2020)

Noonan syndrome
por: van der Burgt, Ineke
Publicado: (2007)

Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency
por: Zavras, Niki, et al.
Publicado: (2015)

Correlation between genetic heterogeneity and variability for response to growth hormone in Noonan syndrome
por: Shin, Young-Lim
Publicado: (2019)

Effect of Growth Hormone Therapy in Patients with Noonan Syndrome: A Retrospective Study
por: Apperley, Louise Jayne, et al.
Publicado: (2020)

Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence
por: Romano, Alicia, et al.
Publicado: (2021)

Growth in Children With Noonan Syndrome and Effects of Growth Hormone Treatment on Adult Height
por: Libraro, Annachiara, et al.
Publicado: (2021)

Transcriptional Hallmarks of Noonan Syndrome and Noonan-Like Syndrome with Loose Anagen Hair
por: Ferrero, Giovanni Battista, et al.
Publicado: (2012)

The research registry - answering the call to register every research study involving human participants
por: Agha, Riaz, et al.
Publicado: (2015)

The Research Registry – Answering the call to register every research study involving human participants
por: Agha, Riaz, et al.
Publicado: (2015)

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status
por: Jorge, Alexander A L, et al.
Publicado: (2022)

Clinical manifestations of Noonan syndrome
por: Digilio, MC, et al.
Publicado: (2001)

Recognition Memory in Noonan Syndrome
por: Costanzo, Floriana, et al.
Publicado: (2021)

Enabling Interactive Answering of Procedural Questions
por: Maitra, Anutosh, et al.
Publicado: (2020)

LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS
por: Ross, Judith L, et al.
Publicado: (2022)

Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with Noonan syndrome
por: Jo, Kyo Jin, et al.
Publicado: (2019)

Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use
por: Hokken-Koelega, Anita, et al.
Publicado: (2011)

The other side of Turner's: Noonan's syndrome
por: Agarwal, Pankaj, et al.
Publicado: (2013)

Noonan syndrome – a new survey
por: Tafazoli, Alireza, et al.
Publicado: (2016)

Personality and Psychopathology in Adults with Noonan Syndrome
por: Roelofs, Renée L., et al.
Publicado: (2019)

Noonan syndrome: improving recognition and diagnosis
por: Zenker, Martin, et al.
Publicado: (2022)

Graph NLU enabled question answering system
por: Varma, Sandeep, et al.
Publicado: (2021)

Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 Gene mutation
por: Kim, Yoo-Mi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d7q4kdaml04hg3nafr2h69fv9h